Daré Bioscience, Inc. (DARE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Daré Bioscience, Inc. (DARE) trades at $2.08 with AI Score 18/100 (Grade F). Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on women's health. Market cap: $19.81M, Sector: Healthcare.
Price live · AI analysis from May 7, 2026Analyst Coverage for DARE: DARE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DARE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DARE: 3/7 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Daré Bioscience, Inc. (DARE) Healthcare & Pipeline Overview
Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on the women's health sector, developing and commercializing therapies for contraception, fertility, and sexual health. Their portfolio includes XACIATO for bacterial vaginosis and other products in clinical development, positioning them as an innovator in women's healthcare solutions.
What Is the Investment Thesis for DARE?
Daré Bioscience presents a focused investment opportunity within the women's health sector. The company's value drivers include the successful commercialization of XACIATO, potential FDA approvals for Ovaprene and Sildenafil Cream, and advancement of its Phase 1-ready and pre-clinical assets. Revenue growth will depend on market penetration of XACIATO and subsequent product launches. Key catalysts include clinical trial results for Ovaprene and Sildenafil Cream expected in late 2026, and partnership agreements for further development and commercialization. However, the company faces risks related to regulatory approvals, competition, and the need for additional financing. With a market cap of $19.81M and negative profit and gross margins, the company's financial performance is highly dependent on future product successes.
Based on FMP financials and quantitative analysis
DARE Key Highlights
- Market capitalization of $19.81M reflects the company's early stage and growth potential in the women's health market.
- Negative profit margin of -1300.7% indicates significant investment in research and development and pre-commercialization expenses.
- Gross margin of -276.2% reflects initial costs associated with product launches and manufacturing agreements.
- Beta of 0.90 suggests the stock is slightly less volatile than the overall market.
- No dividend yield, consistent with a growth-oriented biopharmaceutical company focused on reinvesting earnings into R&D.
Who Are DARE's Competitors?
DARE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PRGO Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions. The company | $11.16 | +1.32% | $1.54B | 44 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DARE's Key Strengths?
- Focused pipeline of women's health products.
- Commercialized product (XACIATO) provides revenue stream.
- Strategic partnerships with established pharmaceutical companies.
- Experienced management team with expertise in women's health.
What Are DARE's Weaknesses?
- Limited financial resources as a clinical-stage company.
- Dependence on regulatory approvals for pipeline products.
- Negative profit and gross margins.
- Small number of employees.
What Could Drive DARE Stock Higher?
- Clinical trial results for Ovaprene expected in late 2026.
- Clinical trial results for Sildenafil Cream expected in late 2026.
- Expansion of XACIATO market share through strategic marketing and distribution.
- Advancement of Phase 1-ready products through clinical development.
- Potential new partnerships and licensing agreements.
What Are the Key Risks for DARE?
- Financial-distress signal — its Altman Z-Score of -10.51 sits in the distress zone (elevated bankruptcy risk).
- Regulatory setbacks or delays in FDA approvals.
- Competition from established pharmaceutical companies.
- Patent expirations.
- Need for additional financing to support clinical development and commercialization.
- Dependence on strategic partners for commercial success.
What Are the Growth Opportunities for DARE?
- Expansion of XACIATO Market Share: Daré Bioscience has the opportunity to increase the market share of XACIATO for bacterial vaginosis through strategic marketing and distribution partnerships. The bacterial vaginosis treatment market is estimated at $748 million in 2023 and is projected to reach $923.8 million by 2033, growing at a CAGR of 2.1%. Effective promotion and physician education could drive adoption of XACIATO, leading to increased revenue and profitability. Timeline: Ongoing.
- Ovaprene Approval and Launch: Ovaprene, a hormone-free monthly vaginal contraceptive, represents a significant growth opportunity. The global contraceptive market is projected to reach $24.6 billion by 2027. If approved, Ovaprene could capture a substantial share of the non-hormonal contraceptive segment. Successful completion of clinical trials and FDA approval are critical milestones. Timeline: Anticipated regulatory submission in 2027, potential launch in 2028.
- Sildenafil Cream Commercialization: Sildenafil Cream for female sexual arousal disorder (FSAD) offers another avenue for growth. The FSAD market is estimated at $2.5 billion. Positive clinical trial results and subsequent FDA approval could position Sildenafil Cream as a leading treatment option. Strategic partnerships for commercialization will be essential. Timeline: Potential regulatory submission in 2027, launch in 2028.
- Advancement of Phase 1-Ready Assets: Daré's Phase 1-ready products, including DARE-HRT1, DARE-VVA1, DARE-FRT1, and DARE-PTB1, represent future growth potential. Each product targets specific unmet needs in women's health, such as vasomotor symptoms, vulvar and vaginal atrophy, and preterm birth prevention. Successful completion of Phase 1 trials and subsequent clinical development could lead to new product launches. Timeline: Phase 1 trials ongoing through 2027, potential product launches starting in 2029.
- Strategic Partnerships and Licensing Agreements: Daré Bioscience can leverage strategic partnerships and licensing agreements to expand its product portfolio and market reach. Collaborations with larger pharmaceutical companies or specialized women's health companies can provide access to additional resources and expertise. The licensing agreement with Organon for XACIATO demonstrates the potential for value creation through partnerships. Timeline: Ongoing.
What Opportunities Does DARE Have?
- Expansion of XACIATO market share.
- FDA approval and launch of Ovaprene and Sildenafil Cream.
- Development of new products for underserved women's health needs.
- Strategic acquisitions or licensing agreements.
What Threats Does DARE Face?
- Competition from established pharmaceutical companies.
- Regulatory setbacks or delays.
- Patent expirations.
- Need for additional financing.
What Are DARE's Competitive Advantages?
- Proprietary formulations and drug delivery technologies.
- Patent protection for key products and technologies.
- Focus on underserved areas within women's health.
- Established partnerships with major pharmaceutical companies.
What Does DARE Do?
Daré Bioscience, Inc., founded with the mission to address unmet needs in women's health, is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and marketing innovative products. The company's focus spans contraception, fertility, and sexual and vaginal health, areas often underserved by traditional pharmaceutical companies. Daré's initial product, XACIATO, a single-dose vaginal gel for bacterial vaginosis, is already on the market through a license agreement with Organon & Co. and Organon International GmbH. Beyond XACIATO, Daré's pipeline includes Ovaprene, a hormone-free monthly vaginal contraceptive in advanced clinical development, and Sildenafil Cream, a topical formulation for female sexual arousal disorder. The company also has several Phase 1-ready products, such as DARE-HRT1 for vasomotor symptoms, DARE-VVA1 for vulvar and vaginal atrophy, and DARE-FRT1 and DARE-PTB1 for preterm birth prevention and luteal phase support. Pre-clinical programs include DARE-LARC1 for reversible contraception, ADARE-204 and ADARE-214 for long-acting injectable contraception, and DARE-RH1 for non-hormonal contraception. Headquartered in San Diego, California, Daré Bioscience operates primarily in the United States, partnering with established companies to expand its commercial reach.
What Products and Services Does DARE Offer?
- Develops therapies for contraception, fertility, and sexual and vaginal health.
- Markets XACIATO, a single-dose vaginal gel for bacterial vaginosis.
- Advances Ovaprene, a hormone-free monthly vaginal contraceptive, through clinical trials.
- Develops Sildenafil Cream for topical administration to treat female sexual arousal disorder.
- Creates intravaginal rings for hormone therapy and preterm birth prevention.
- Researches non-hormonal contraception options for both men and women.
How Does DARE Make Money?
- Develops and out-licenses women's health products.
- Generates revenue through product sales (XACIATO) and potential milestone payments from partners.
- Focuses on clinical development and regulatory approval of its pipeline products.
- Partners with larger pharmaceutical companies for commercialization and distribution.
What Industry Does DARE Operate In?
The biotechnology industry is characterized by high innovation, long development cycles, and significant regulatory hurdles. The women's health segment represents a growing market driven by increasing awareness and demand for specialized treatments. Daré Bioscience operates in a competitive landscape that includes established pharmaceutical companies and smaller biotech firms. The company's focus on underserved areas within women's health, such as hormone-free contraception and female sexual dysfunction, positions it to capture niche markets. The global women's health market is projected to reach $51.4 billion by 2027, growing at a CAGR of 4.2% from 2020.
Who Are DARE's Key Customers?
- Women seeking treatments for bacterial vaginosis.
- Women seeking contraception options.
- Women seeking treatments for female sexual arousal disorder.
- Healthcare providers specializing in women's health.
Company Profile
Daré Bioscience, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Sabrina Martucci Johnson. DARE has traded publicly since 2014.
Key Financial Metrics
Return on assets is -43.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -55.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -43.1%, the inverse of the P/E and a quick read on earnings relative to price.
DARE Valuation & Market Position
With a $19.81M market cap, Daré Bioscience, Inc. sits in the micro-cap segment of the market. Relative to its peer group, DARE's quantitative score of 18/100 is below the peer average of 71/100.
Quarterly Financial Performance: Daré Bioscience, Inc.
Revenue for Daré Bioscience, Inc. came in at $152K during Q1 2026, a 85.1% contraction versus the preceding quarter. The company recorded a net loss of $3.0M, with diluted EPS of $-0.21. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
F-Score 5/9Financial Health
Daré Bioscience, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -10.51 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Daré Bioscience, Inc. revenue of about $2.1M for fiscal 2026, with EPS near $-0.95.
DARE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the potential of their pipeline.
- Community sentiment has shifted positively, with discussions highlighting the excitement around upcoming product launches and clinical trial results.
- Bullish analysts emphasize the company's innovative approach to women's health, which is gaining traction in a growing market.
- Recent partnerships and collaborations have strengthened their position, showcasing trust from industry players in Daré's capabilities.
Bear Case
- Some investors express concerns over the company's cash runway, raising questions about funding and operational sustainability in the near term.
- Negative sentiment has emerged around the competitive landscape, with competitors making significant advancements that could overshadow Daré's offerings.
- Recent clinical trial results have faced scrutiny, leading to skepticism about the efficacy of their key products, impacting overall investor confidence.
- Market perception remains cautious, with some community members highlighting the volatility and risks associated with biotech investments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $152,455 | -$3M | -$0.21 |
| Q4 2025 | $1M | -$1M | -$0.10 |
| Q3 2025 | $2,262 | -$4M | -$0.28 |
Based on FMP financials and quantitative analysis
DARE Latest News
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · May 15, 2026
-
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga · May 14, 2026
-
Earnings Scheduled For May 14, 2026
benzinga · May 14, 2026
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
DARE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DARE.
Price Targets
Wall Street price target analysis for DARE.
DARE MoonshotScore
What does this score mean?
The MoonshotScore rates DARE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Daré Bioscience, Inc. Analysis
Leadership: Sabrina Martucci Johnson
President and Chief Executive Officer
Sabrina Martucci Johnson has served as the President and CEO of Daré Bioscience since its inception. She has extensive experience in the healthcare industry, with a focus on women's health. Prior to Daré, she held leadership positions at WomanCare Global and various other healthcare companies. Her background includes expertise in product development, commercialization, and strategic partnerships. She holds a degree in Chemical Engineering from Princeton University and an MBA from the University of California, San Diego.
Track Record: Under Sabrina Martucci Johnson's leadership, Daré Bioscience has successfully developed and commercialized XACIATO, secured strategic partnerships with companies like Organon, and advanced a pipeline of innovative women's health products through clinical development. She has overseen multiple financing rounds to support the company's growth and has built a strong team focused on addressing unmet needs in women's health.
Common Questions About DARE (Healthcare)
What does Daré Bioscience, Inc. do?
Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and marketing innovative products for women's health. Their focus spans contraception, fertility, and sexual and vaginal health. The company's lead product, XACIATO, is a single-dose vaginal gel for the treatment of bacterial vaginosis and is being commercialized through a partnership with Organon. Daré's pipeline includes Ovaprene, a hormone-free monthly vaginal contraceptive, and Sildenafil Cream for female sexual arousal disorder, along with several other products in various stages of clinical development. The company aims to address unmet needs in the women's health market through innovative therapies and strategic partnerships.
What do analysts say about DARE stock?
Analyst coverage of Daré Bioscience is limited, reflecting its status as a small-cap, clinical-stage biopharmaceutical company. Generally, analysts focus on the potential of Daré's pipeline products, particularly Ovaprene and Sildenafil Cream, and their potential market impact if approved. Valuation metrics are heavily influenced by projected future revenues and the likelihood of regulatory approvals. Given the inherent risks associated with biotech companies, analyst opinions often emphasize the importance of clinical trial results and the company's ability to secure additional funding. Investors should conduct their own due diligence and consider the risks before investing.
What are the main risks for DARE?
Daré Bioscience faces several key risks inherent to the biopharmaceutical industry. These include the risk of regulatory setbacks or delays in obtaining FDA approvals for its pipeline products, particularly Ovaprene and Sildenafil Cream. Competition from established pharmaceutical companies with greater resources and market presence poses another significant risk. The company also faces the risk of patent expirations, which could impact the exclusivity and profitability of its products. Furthermore, as a clinical-stage company, Daré relies on securing additional financing to fund its research and development activities, which may dilute existing shareholders or increase debt. Dependence on strategic partners for commercialization also presents a risk if these partnerships are not successful.
What are the key factors to evaluate for DARE?
Daré Bioscience, Inc. (DARE) holds an AI score of 18/100 (low). Not financial advice.
How frequently does DARE data refresh on this page?
DARE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DARE's recent stock price performance?
Daré Bioscience, Inc. (DARE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focused pipeline of women's health products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DARE overvalued or undervalued right now?
Valuing Daré Bioscience, Inc. (DARE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DARE?
Before investing in Daré Bioscience, Inc. (DARE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and company filings.
- Financial data is as of the most recent reporting period.
- Forward-looking statements are subject to change based on market conditions and company performance.